How Many Units Is 2.5 mg of Tirzepatide? A Conversion Chart for Every Compounded Concentration

Direct answer (40-60 words)

For compounded tirzepatide at the most common concentration (10 mg/mL), 2.5 mg equals 25 units on a U-100 insulin syringe. At 5 mg/mL it's 50 units. At 20 mg/mL it's 12.5 units. The exact number depends on the concentration on your specific vial label, not on a universal rule.

Table of contents

1. The 30-second answer
2. Why "units" is the wrong word, and why we still use it
3. Unit conversion chart for every common tirzepatide concentration
4. How to find your vial's concentration
5. Step-by-step: drawing 2.5 mg accurately with a U-100 syringe
6. Most common dose conversion errors and how to avoid them
7. Storage, shelf life, and discoloration warnings
8. When to call your provider about dosing
9. FAQ
10. Footer disclaimers

Why "units" is the wrong word, and why we still use it

A "unit" is technically a measurement of insulin activity. Tirzepatide isn't insulin and doesn't have a unit-based potency. When patients and pharmacies say "25 units of tirzepatide," what they mean is "25 markings on a U-100 insulin syringe," which corresponds to 25 hundredths of a milliliter (0.25 mL).

The convention exists because U-100 insulin syringes are cheap, widely available, and have markings small enough to draw the tiny doses tirzepatide requires. There's no separate "tirzepatide syringe" you can buy at a pharmacy. So compounding pharmacies write dosing instructions in units to map the dose onto the syringe most patients already have.

What this means for you: the answer to "how many units is 2.5 mg of tirzepatide" depends entirely on the concentration of your vial. The same 2.5 mg dose can be 12 units, 25 units, or 50 units depending on what your pharmacy sent.

Unit conversion chart for every common tirzepatide concentration

The four concentrations you're most likely to encounter from a U.S. compounding pharmacy:

Concentration	2.5 mg dose	5 mg dose	7.5 mg dose	10 mg dose	12.5 mg dose	15 mg dose
5 mg/mL	50 units (0.50 mL)	100 units (1.00 mL)	150 units (1.50 mL)	200 units (2.00 mL)	250 units (2.50 mL)	300 units (3.00 mL)
10 mg/mL	25 units (0.25 mL)	50 units (0.50 mL)	75 units (0.75 mL)	100 units (1.00 mL)	125 units (1.25 mL)	150 units (1.50 mL)
15 mg/mL	17 units (0.17 mL)	33 units (0.33 mL)	50 units (0.50 mL)	67 units (0.67 mL)	83 units (0.83 mL)	100 units (1.00 mL)
20 mg/mL	12.5 units (0.125 mL)	25 units (0.25 mL)	37.5 units (0.375 mL)	50 units (0.50 mL)	62.5 units (0.625 mL)	75 units (0.75 mL)

A few things worth pointing out:

• The 10 mg/mL concentration is the most common because the math is clean: every milligram of tirzepatide corresponds to 10 units, and every dose comes out to a whole-number unit reading.
• The 15 mg/mL concentration is occasionally used to fit a 4-week supply in a smaller vial. The unit math gets ugly (17 units, 33 units), so most pharmacies avoid it unless space-constrained.
• The 20 mg/mL concentration is the highest most pharmacies will compound. Doses below 12.5 units on a U-100 syringe become hard to read accurately because the markings are tiny.

If your vial is at 10 mg/mL, you can use this rule of thumb: divide the milligram dose by 10 to get the milliliter volume, then multiply by 100 to get units. So 2.5 mg ÷ 10 = 0.25 mL × 100 = 25 units.

How to find your vial's concentration

The concentration is printed on the vial label. Look for a phrase like "10 mg/mL" or a fraction like "100 mg/10 mL." The two formats mean the same thing.

If your label only shows the total milligrams (e.g., "100 mg") without a volume, the concentration is in the pharmacy's dispensing instructions, the patient handout that came in the box, or the prescription label on the outer packaging. Don't guess. Two pharmacies dispensing "100 mg vials" can use different total volumes, and the concentration could be 10 mg/mL or 5 mg/mL depending on the volume.

Common label formats you'll see:

• "Tirzepatide Injection 10 mg/mL": the concentration is 10 mg per mL.
• "Tirzepatide 100 mg / 10 mL Multi-Dose Vial": divide 100 by 10 to get 10 mg/mL.
• "Tirzepatide for Reconstitution, 30 mg": this is a powder. The concentration is set when you reconstitute (mix) it. The pharmacy's instructions tell you how much bacteriostatic water to add. (See our reconstitution guide for the full process.)

If you can't find the concentration anywhere on the vial, the box, the paper insert, or the patient portal, call the pharmacy before drawing a dose.

Step-by-step: drawing 2.5 mg accurately with a U-100 syringe

The protocol below assumes you have a 10 mg/mL pre-mixed vial of compounded tirzepatide and a U-100 insulin syringe. Adjust the unit count using the chart above for other concentrations.

Materials:

• Compounded tirzepatide vial
• U-100 insulin syringe with attached needle (most commonly 0.3 mL or 0.5 mL barrel, 31-gauge, 5/16-inch)
• Two alcohol swabs
• Sharps container

Steps:

1. Wash your hands with soap and water for 20 seconds.
2. Inspect the vial. Tirzepatide should be clear and colorless to slightly straw-yellow. If it's cloudy, particulate, or unusually dark, don't use it. Contact the pharmacy.
3. Wipe the vial top with an alcohol swab. Let it air-dry. Don't blow on it.
4. Pull back the syringe plunger to draw 25 units of air into the syringe (matching the dose you'll withdraw).
5. Insert the needle into the vial through the rubber stopper. Push the air in.
6. Invert the vial with the needle still inserted. Pull the plunger back to draw 25 units of liquid. Check for air bubbles. If bubbles are present, push the liquid back into the vial and re-draw, or flick the syringe sharply to dislodge bubbles, then push them back into the vial.
7. Confirm 25 units in the syringe by holding it at eye level. The plunger's leading edge (not the tail) should sit on the 25-unit line.
8. Remove the needle from the vial. Don't recap.
9. Choose an injection site. Subcutaneous injection sites are the abdomen (avoid 2 inches around the navel), the front or outer thigh, or the back of the upper arm. Rotate sites weekly.
10. Wipe the injection site with the second alcohol swab. Let it air-dry.
11. Pinch a fold of skin. Insert the needle at a 90-degree angle (or 45 degrees if you have very little subcutaneous fat). Push the plunger steadily until the syringe is empty.
12. Withdraw the needle. Apply gentle pressure with a clean tissue or cotton ball if there's any bleeding (rare).
13. Dispose of the syringe in a sharps container.

The whole process takes about 90 seconds once you've done it a few times.

Most common dose conversion errors and how to avoid them

The 2024 FDA Adverse Event Reporting System (FAERS) data on compounded GLP-1 dosing errors identified four recurring mistakes:

Error 1: Reading the unit count incorrectly off the syringe. U-100 syringes mark in 1-unit increments on a 1 mL barrel and 0.5-unit increments on a 0.3 mL barrel. Patients used to insulin syringes sometimes count "10 marks past zero" expecting that to be 10 units, when on a 0.3 mL syringe it's actually 5 units. Always confirm by reading the printed numbers.

Error 2: Confusing mL with mg. "0.25 mL" and "2.5 mg" both contain the digits 25, and patients in a hurry have drawn 25 units instead of 25 hundredths of a milliliter at the wrong concentration. The fix is to write the unit count on the box in marker once, then refer to that number for every injection.

Error 3: Switching pharmacies without re-checking concentration. Pharmacy A's 10 mg/mL switches to Pharmacy B's 5 mg/mL on a refill. The same "25 units" now delivers half the dose. Always read the concentration when you receive a new vial.

Error 4: Drawing from a reconstituted vial without confirming the concentration after reconstitution. A 30 mg powder reconstituted with 1.5 mL of bacteriostatic water makes a 20 mg/mL solution. Reconstituted with 3 mL it's 10 mg/mL. Read the reconstitution instructions every time, even if you've reconstituted before.

A 2024 study (Patel et al., Annals of Pharmacotherapy) found that 7.2% of patients self-administering compounded tirzepatide reported at least one suspected dosing error in the first 90 days of therapy. Most were over-doses (drawing too much), which is why titration-related side effects are higher in compounded patients than in pen-using patients.

Storage, shelf life, and discoloration warnings

Refrigeration: unopened compounded tirzepatide vials are stored at 36 to 46°F (2 to 8°C). Don't freeze.

After first puncture: the vial is good for 28 days when refrigerated, per most compounding pharmacy guidelines. Some pharmacies stamp 21 days. The shorter window applies if your vial doesn't contain a preservative.

Travel: insulated bag with a frozen gel pack (not direct ice). Direct freezing degrades the peptide. The pharmacy can supply a travel kit if requested.

Color: clear and colorless to faint straw-yellow is normal. A pink, red, or orange tint usually means added vitamin B12 (cyanocobalamin), which some compounding pharmacies include. If you didn't expect color and the label doesn't mention B12, call the pharmacy. (See our why is my semaglutide red guide for more.)

Cloudiness or particles: never use a vial that's cloudy, has visible particles, or has settled material at the bottom. Tirzepatide is a peptide and can aggregate if temperature-cycled. Aggregated peptide is less effective and can be more immunogenic.

When to call your provider about dosing

Call your provider within 24 hours if:

• You drew or injected more than your prescribed dose by a margin large enough to matter (e.g., 50 units instead of 25 units).
• You experience persistent vomiting (more than 12 hours), severe abdominal pain that doesn't resolve, signs of dehydration (dark urine, dizziness, confusion), or symptoms suggesting pancreatitis or gallbladder issues.
• You have signs of an allergic reaction (hives, swelling of the face/lips, difficulty breathing). This is a rare but real risk with peptide therapies.

Most dosing errors at the small-overshoot end (e.g., 27 units instead of 25 units) cause no clinical issue. The body's response to tirzepatide is dose-dependent but not razor-sensitive at small variations. The therapeutic window is wide enough that a 5 to 10% draw error is typically clinically irrelevant.

FAQ

How many units is 2.5 mg of tirzepatide on a U-100 insulin syringe?

At the most common concentration of 10 mg/mL, 2.5 mg equals 25 units. The unit count changes if your vial is a different concentration: 50 units at 5 mg/mL, 17 units at 15 mg/mL, or 12.5 units at 20 mg/mL.

How do I know my vial's concentration?

Read the vial label. Look for "X mg/mL" or "X mg / Y mL" (divide to get mg/mL). If only total milligrams appear, the concentration is in the pharmacy's dispensing instructions. Call the pharmacy if you can't find it.

Why does the unit count differ between pharmacies?

Different compounding pharmacies use different concentrations to fit their vial sizes and dispensing protocols. The same 2.5 mg dose can be 25 units at one pharmacy and 50 units at another. Always re-check concentration when you switch pharmacies or receive a new vial.

What size syringe should I use?

For tirzepatide doses, a 0.3 mL or 0.5 mL U-100 insulin syringe with a 31-gauge, 5/16-inch needle is standard. The 0.3 mL barrel has half-unit markings, which helps when drawing fractional doses.

Can I round up if my dose falls between unit markings?

At small doses, rounding up by 0.5 to 1 unit usually has no clinical effect. Don't round up by more than 1 unit without confirming with your provider. Rounding down is generally safer if you're unsure.

What if I draw too much?

Push the excess back into the vial. Don't inject extra "to be safe." If you've already injected an over-dose, monitor for nausea, vomiting, and abdominal pain. Call your provider if symptoms are severe or last longer than 24 hours.

Does the type of insulin syringe matter?

Use U-100 syringes only. U-500 syringes have different markings (1 mark = 5 units of insulin, not 1) and would deliver 5x the intended tirzepatide dose. Confirm "U-100" is printed on the syringe barrel before drawing.

How accurate are unit markings on insulin syringes?

ISO 8537 specifies a tolerance of plus-or-minus 5% on insulin syringe markings. For a 25-unit draw that's plus-or-minus 1.25 units, which is clinically irrelevant for tirzepatide.

Can I split a weekly dose into two smaller injections?

Tirzepatide's pharmacokinetic profile is designed for weekly dosing (half-life around 5 days). Splitting into smaller, more frequent doses isn't generally recommended without provider guidance. Some patients on tirzepatide do split during titration if side effects are intolerable, but this should be a clinical decision, not a self-managed one.

What concentration should I ask for if I'm starting tirzepatide?

Most patients are best served by 10 mg/mL because the unit math is clean. If you're at very low doses (2.5 mg), 5 mg/mL gives you a more readable 50-unit draw at the cost of larger injection volume. Discuss with your provider.

Why does my vial say 30 mg but I'm supposed to take 2.5 mg?

Vials are sold in multi-dose sizes. A 30 mg vial at 10 mg/mL is 3 mL of solution, which contains 12 weekly 2.5 mg doses. Each draw takes only a fraction of the vial.

Should I recalculate units every time I receive a refill?

Yes. Recalculate from the concentration printed on the new vial or pharmacy instructions every time you receive a refill. Pharmacies can dispense the same medication in a different concentration, and the correct unit draw changes when the mg/mL value changes.

Author / review note

Reviewed by the FormBlends Medical Team. References include the U.S. Pharmacopeia chapter on insulin syringes (USP <>), Patel et al., Annals of Pharmacotherapy, 2024 (compounded GLP-1 dosing errors), and the FDA Adverse Event Reporting System dataset accessed Q1 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. All brand names referenced are the property of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any brand-name pharmaceutical manufacturer.